Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults. It starts in the lining of tiny tubes in the kidney, which filter waste from your blood to make urine. Many people don't notice RCC early because it often grows silently without symptoms.
So, how do you know if something’s wrong? Common signs include blood in the urine, pain in the side or lower back, a lump near your ribs, or unexplained weight loss. But these can mean other issues too. That’s why doctors use scans like ultrasounds, CT scans, or MRIs to see what's really going on inside your kidneys.
No one knows exactly why RCC happens, but a few risk factors raise your chance. Smoking greatly ups your risk, so does obesity, and having high blood pressure. Some rare genetic conditions can also play a part. The good news? Avoiding smoking, staying active, and managing blood pressure lower your chance of RCC.
Treatment depends on how big the tumor is and if cancer has spread. Often, surgery to remove part or all the kidney is the first step. Minimally invasive surgery is common nowadays, meaning smaller cuts and quicker recovery. If cancer has spread beyond the kidney, targeted therapy or immunotherapy drugs may be used to slow it down. Radiation and chemotherapy are less commonly used but can help in certain cases.
If you or someone you know is dealing with RCC, regular doctor visits and early check-ups make a big difference. Catching it early widens treatment options and improves outcomes.
Remember, renal cell carcinoma doesn’t always come with clear signals, so if you notice persistent symptoms like persistent flank pain or blood in urine, don’t wait to get checked. With today’s medical advances and proper care, many people manage RCC well and live active lives.
A study presented at the 2024 ASCO Annual Meeting has confirmed the potential of circulating kidney injury molecule-1 (KIM-1) as a prognostic biomarker in renal cell carcinoma. This study involved a comprehensive analysis of protein biomarkers and underscored the significance of KIM-1 in predicting disease recurrence and survival outcomes, highlighting its promise in patient monitoring and treatment strategies.
Read more© 2025. All rights reserved.